Anticoagulation Therapy in Patients Post-TAVR

Slides:

Advertisements

Similar presentations

An audit of the antithrombotic therapy for the management of valve repair or replacement Gellatly RM 1,2, Maydelmin D 1, Connell C 1, Marasco S 3, Zimmet.

Advertisements

Addressing the Challenges in Primary and Secondary Stroke Prevention

Acute Hypertension Management Optimizing Door-to-Needle Time in Ischemic Stroke.

Atrial Fibrillation and PCI

Anticoagulants in Interventional Cardiology:

Managing Bleeds in Patients Anticoagulated With Warfarin and Other Agents.

Getting the 411 on TAVR Trials

Objective Assessment of RA: Expanding the Horizons

NOACs, AF, and PCI: What Do the Latest Data Suggest?

When Is Adding Aspirin to NOACs Worth the Risk?

Barriers to Oral Anticoagulant Use for Stroke Prevention in AF

Thrombosis, Cancer, and NOACs

Emerging Data on ACS Management From ACC

Applying New Data in Practice:

Pavel OVERTCHOUK Paul GUEDENEY Stéphanie ROUANET Jean Philippe VERHOYE

Introduction ESC Annual Meeting in Review: NOACs and NVAF: Real-World Data, Guidelines, and More.

Advances in Coronary Artery Disease: Moving Beyond Antiplatelet Therapy.

Unmet Needs in the Secondary Prevention in ACS

American Heart Association Scientific Sessions

Clinical Presentations of VTEa,b NOACs VTE Acute Treatment Trials.

Antiplatelet Therapy Post-ACS: Bridging the CAD Continuum

New Perspectives in CAD and PAD: Weighing the Latest Evidence

What Has Been Tried and What Is True?

Strategies to Improve Adherence and Persistence in the Treatment of Hypertension.

Selecting NOACs for High-Risk Patients

Tailoring Antiplatelet Therapy in PCI

A Case Challenge: Anticoagulant Choices for Acute PE

Antiplatelet Therapy and Secondary Prevention

The Essentials for Secondary Stroke Prevention

Counseling Patients About Germline BRCA Mutations

Assessing the State of Statin Therapy

Assessing the Risk for Stroke in Patients With Atrial Fibrillation

A Unified Approach to Anticoagulant Therapy in ACS: What's Missing?

Treatment Options to Consider

Introduction. A Reality Check on BP Goals and Optimizing Patient Adherence to Treatment.

AF and PCI in Practice.

Antithrombotic Protection in CAD and HF

TAVR and the Risk of Thrombosis

Rheumatoid Arthritis 2015 Guidelines What's New? What's Different?

What Anticoagulant Registries Are Revealing

Watching for the Patient With AF: Latest Advances and Technologies

Radical New Concepts in Lipid Management

The Importance of Getting the Dose Right in HF

Taking the "Cryptogenic" Out of Cryptogenic Stroke

Aspects to be considered by the Heart Team for the decision between TAVR and SAVR in patients at increased surgical risk. Aspects to be considered by the.

Identifying High-Risk AF Patients

The Road to Quality Improvement in HER2-Positive Breast Cancer

Trials and Tribulations in VTE: How Do Real-World Data Fit In?

Factor Xa Inhibitors in PAD

Cancer-Associated Thrombosis

Improving Outcomes in AF: Do the NOACs Hold Their Promise In The Real World?

Antithrombotic Therapy in PAD

Antithrombotic Therapy in Vascular Protection: From CAD to HF

Antithrombotics in Arterial Disease: Focus on Coronary Disease

Program Goals Background: Anticoagulation in Patients With VTE.

The Challenge of AF and PCI: Practical Strategies to Improve Outcomes

A Multidisciplinary Perspective on the Management of Hypoparathyroidism.

Antiplatelet Therapy Post-ACS: Bridging the CAD Continuum

Disease Burden of VTE Phases of VTE Treatment.

Taking the "Cryptogenic" Out of Cryptogenic Stroke

Pavel OVERTCHOUK Paul GUEDENEY Stéphanie ROUANET Jean Philippe VERHOYE

So Many Guidelines, So Little Time:

VTE Treatment and Secondary Prevention VTE Treatment Trials Initial Dosing.

Championing Evidence-Based Care in Patients With Acute Low Back Pain

Uptitration of Medications in HF: Start Low but Aim High and Stay High

ESC Guideline on the Management of STEMI Recommendation for DAPT

PCSK9 Inhibitors and Real-World Evidence

Treating Pulmonary Embolism Today

Can the Dual vs Triple Therapy Controversy in Patients With AF Undergoing PCI Be Put to Rest?

Presentation transcript:

Anticoagulation Therapy in Patients Post-TAVR

Use of TAVR Is Expanding

DAPT in TAVR

STARS

DAPT in TAVR

Management During and After TAVR

Post-TAVR

Post-TAVR Anticoagulation

Rationale for Anticoagulation

BRAVO-3

Current ACC/AHA, ACCP, and ESC Guideline Recommendations for Antithrombotic Therapy Within 3 mo After Bioprosthetic Valve Replacement

ATLANTIS Trial Design Apixaban in Patients Who Underwent a Clinically Successful TAVI Procedure

GALILEO Trial Design

Summary

Summary (cont)

Abbreviations

Abbreviations (cont)